TARSONS2024-07-012024-09-30 TARSONS2024-07-012024-09-30 TARSONS2024-07-012024-09-30in-bse-fin:OneOperatingExpenses01Member TARSONS2024-07-012024-09-30in-bse-fin:FourOperatingExpenses01Member TARSONS2024-09-30 TARSONS2024-07-012024-09-30in-bse-fin:OneReportableSegmentRevenue01Member TARSONS2024-07-012024-09-30in-bse-fin:OneReportableSegmentRevenue02Member TARSONS2024-07-012024-09-30in-bse-fin:OneReportableSegmentRevenue03Member TARSONS2024-07-012024-09-30in-bse-fin:FourReportableSegmentRevenue01Member TARSONS2024-07-012024-09-30in-bse-fin:FourReportableSegmentRevenue02Member TARSONS2024-07-012024-09-30in-bse-fin:FourReportableSegmentRevenue03Member TARSONS2024-07-012024-09-30in-bse-fin:OneReportableSegmentResults01Member TARSONS2024-07-012024-09-30in-bse-fin:OneReportableSegmentResults02Member TARSONS2024-07-012024-09-30in-bse-fin:OneReportableSegmentResults03Member TARSONS2024-07-012024-09-30in-bse-fin:FourReportableSegmentResults01Member TARSONS2024-07-012024-09-30in-bse-fin:FourReportableSegmentResults02Member TARSONS2024-07-012024-09-30in-bse-fin:FourReportableSegmentResults03Member TARSONS2024-07-012024-09-30in-bse-fin:OneReportableSegmentAssets01Member TARSONS2024-07-012024-09-30in-bse-fin:OneReportableSegmentAssets02Member TARSONS2024-07-012024-09-30in-bse-fin:OneReportableSegmentAssets03Member TARSONS2024-07-012024-09-30in-bse-fin:OneReportableSegmentLiabilities01Member TARSONS2024-09-30in-bse-fin:OneReportableSegmentLiabilities01Member TARSONS2024-07-012024-09-30in-bse-fin:OneReportableSegmentLiabilities02Member TARSONS2024-09-30in-bse-fin:OneReportableSegmentLiabilities02Member TARSONS2024-07-012024-09-30in-bse-fin:OneReportableSegmentLiabilities03Member TARSONS2024-09-30in-bse-fin:OneReportableSegmentLiabilities03Member TARSONS2024-07-012024-09-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member TARSONS2024-07-012024-09-30in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member TARSONS2024-07-012024-09-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member TARSONS2024-07-012024-09-30in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 543399 TARSONS NOTLISTED Tarsons Products Limited Equity 2024-04-01 2025-03-31 2024-11-07 2024-10-28 INR Millions Half yearly 16:30:00 16:55:00 2024-11-07 2024-11-07 true Cash Flow Indirect Not applicable Geographical 2024-07-01 2024-09-30 Unaudited Consolidated 992490000.00 84250000.00 1076740000.00 182920000.00 129640000.00 13680000.00 161120000.00 48380000.00 140300000.00 252050000.00 928090000.00 148650000.00 0.00 148650000.00 35770000.00 9970000.00 45740000.00 0.00 102910000.00 0.00 0.00 0.00 0.00 102910000.00 -30080000.00 72830000.00 0.00 0.00 0.00 0.00 106410000.00 2 1.93 1.93 0.00 0.00 1.93 1.93 1. The Statement of Consolidated Unaudited Financial Results includes results of the following entities (100% Shareholding as of September 30, 2024),together referred as Group : a. Tarsons Products Limited, India - Holding Company b. Tarsons Life Science Pte. Ltd., Singapore (from November 10, 2023) - Subsidiary of Tarsons Products Limited, India c. Nerbe plus GmbH & Co. KG, Germany (from January 1, 2024) - Subsidiary of Tarsons Life Science Pte. Ltd., Singapore d. Nerbe R&D GmbH, Germany (from January 1, 2024) - Subsidiary of Tarsons Life Science Pte. Ltd., Singapore 2. The Statement of Consolidated Unaudited Financial Results for the quarter and half year ended September 30, 2024 (“Consolidated Financial Results”) have been reviewed by the Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on November 7, 2024. 3. The aforesaid Consolidated Unaudited Financial Results has been prepared in accordance with the Indian Accounting Standards (“Ind AS”) prescribed under Section 133 of the Companies Act, 2013, as amended (the Act ) read with relevant rules thereunder and in terms of Regulations 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations'). 4. The Holding Company had incorporated a Wholly Owned Subsidiary on November 10, 2023 and hence prepared the consolidated financial results from the quarter and nine months ended December 31, 2023 for the first time during the financial year ended March 31, 2024. The Holding Company did not have any subsidiary, associate or joint venture as on September 30, 2023. Accordingly, the corresponding figures for the quarter and half year ended September 30, 2023 is not required to be furnished in the Consolidated Financial Results. 5. During the year ended March 31, 2024, the Group has completed the acquisition of Nerbe Plus GmbH & Co KG and Nerbe R&D GmbH (collectively known as Nerbe Group ) through its wholly owned subsidiary, Tarsons Life Science Pte Ltd ( TLSPL ) incorporated in Singapore on November 10, 2023. Consequent to the acquisition, TLSPL has acquired 100% controlling stake of the Nerbe Group with effect from January 1, 2024. The Nerbe Group is involved in the business of distribution of medical and laboratory disposables in Germany. 6. During the import of machinery, certain components were damaged during transit to India. The Holding Company has estimated the amount of loss and has filed insurance claim which is under process. The Holding Company has recorded a total provision of INR 63.44 million and INR 93.44 million during the quarter and half year ended September 30, 2024 respectively in relation to damage of such components. The Holding Company will continue pursuing the insurance claim. 7. The Board of Directors of the Holding Company in its meeting held on May 30, 2024 had recommended a dividend of Rs.2/- per fully paid up Equity share of Rs. 2/- each for the financial year 2023-24 which was approved by the shareholders in annual general meeting held on September 27, 2024. 8. The Group is primarily engaged in the business of manufacturing and selling of plastic laboratory products and certain scientific instruments, which represents a single business. Operating segments have been identified based on how the Chief Operating Decision Maker (CODM) reviews and assesses the Group’s performance, which is on the basis of the different geographical areas wherein major entities within the Group operate. Geographical 2024-04-01 2024-09-30 Unaudited Consolidated 1840460000.00 113320000.00 1953780000.00 385690000.00 280560000.00 -63200000.00 322010000.00 91540000.00 250620000.00 474750000.00 1741970000.00 211810000.00 0.00 211810000.00 60740000.00 8000000.00 68740000.00 0.00 143070000.00 0.00 0.00 0.00 0.00 143070000.00 -26240000.00 116830000.00 0.00 0.00 0.00 0.00 106410000.00 2 2.69 2.69 0.00 0.00 2.69 2.69 Other Expenses 252050000.00 Other Expenses 474750000.00 0.00 3947030000.00 2168050000.00 0.00 325250000.00 343760000.00 0.00 0.00 0.00 0.00 0.00 0.00 36580000.00 36580000.00 0.00 1095080000.00 7915750000.00 1393630000.00 0.00 698500000.00 199640000.00 163940000.00 0.00 450000.00 1062530000.00 0.00 171100000.00 2627260000.00 0.00 0.00 10543010000.00 106410000.00 6032650000.00 6139060000.00 6139060000.00 1599630000.00 0.00 97030000.00 1696660000.00 2430000.00 100170000.00 0.00 405010000.00 2204270000.00 1449090000.00 161480000.00 519030000.00 2129600000.00 46080000.00 24000000.00 0.00 0.00 2199680000.00 0.00 0.00 4403950000.00 10543010000.00 Germany 191380000.00 India 801110000.00 Rest of the World 0.00 Germany 390980000.00 India 1449480000.00 Rest of the World 0.00 992490000.00 1840460000.00 -120000.00 -230000.00 992610000.00 1840690000.00 Germany 21540000.00 India 317420000.00 Rest of the World -3710000.00 Germany 45440000.00 India 512960000.00 Rest of the World -8530000.00 335250000.00 549870000.00 48380000.00 91540000.00 138220000.00 246520000.00 148650000.00 211810000.00 Germany 1246370000.00 India 9820880000.00 Rest of the World 1117770000.00 12185020000.00 -1642010000.00 10543010000.00 Germany 618380000.00 India 3529610000.00 Rest of the World 1225520000.00 5373510000.00 -969560000.00 4403950000.00 91540000.00 -106370000.00 79520000.00 0.00 -110880000.00 0.00 0.00 -96640000.00 0.00 5510000.00 0.00 -5250000.00 0.00 250620000.00 0.00 -80000.00 0.00 -17270000.00 0.00 -34440000.00 0.00 5090000.00 0.00 0.00 0.00 0.00 0.00 85680000.00 0.00 136850000.00 348660000.00 0.00 0.00 0.00 128960000.00 0.00 219700000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 8740000.00 589370000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5090000.00 0.00 -1800000.00 0.00 -577340000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2732010000.00 2253810000.00 0.00 2750000.00 0.00 89610000.00 0.00 0.00 385840000.00 28200000.00 340000.00 28540000.00 171100000.00 199640000.00 Remeasurements of post-employment benefit obligations -260000.00 Remeasurements of post-employment benefit obligations -520000.00 -260000.00 -520000.00 -70000.00 -140000.00 Foreign exchange translation reserven -29890000.00 Foreign exchange translation reserven -25860000.00 -29890000.00 -25860000.00 0.00 0.00